The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

Pedro Barata, Moshe C Ornstein, Jorge A Garcia


Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.


Advanced renal cell carcinoma, immunotherapy, mTOR inhibitors, PD-1/PD-L1, VEGF inhibitors

Full Text:



Article Metrics

Metrics Loading ...

Copyright (c) 2017 pedro barata

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.